Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMFLXN)

Drug Name

AD-452 Drug Info

Synonyms

RS(+)-mefloquine; (+)-erythro-mefloquine

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cytokine receptor unspecific (CRF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IRX-2	DMODLN7	Acute myeloid leukaemia	2A60	Phase 2	[3]
JTE-607	DM1BQFY	Sepsis	1G40-1G41	Discontinued in Phase 2	[4]
VP-025	DM0HZBU	Alzheimer disease	8A20	Discontinued in Phase 1	[5]
VG-106	DMY0V6J	Solid tumour/cancer	2A00-2F9Z	Terminated	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytokine receptor unspecific (CRF)	TTXM6JN	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00141934) A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.. U.S. National Institutes of Health.
2	Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9.
3	Clinical pipeline report, company report or official report of IRX Therapeutics.
4	JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8.
5	List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Dis 2007;4:443-486.
6	WO patent application no. 2011,0955,45, Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same.